Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett Sells 1,860 Shares

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 1,860 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $71.50, for a total value of $132,990.00. Following the transaction, the chief operating officer now owns 141,323 shares of the company’s stock, valued at $10,104,594.50. This represents a 1.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Wednesday, May 14th, Roger Adsett sold 1,925 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $126,299.25.
• On Tuesday, May 13th, Roger Adsett sold 7,482 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $507,354.42.

Insmed Price Performance

Shares of INSM stock opened at $73.69 on Thursday. Insmed Incorporated has a 52-week low of $55.74 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $13.42 billion, a P/E ratio of -13.18 and a beta of 0.84. The stock has a 50 day moving average price of $69.32 and a 200 day moving average price of $72.99.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same period in the prior year, the business posted ($1.06) earnings per share. Insmed’s revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analysts Set New Price Targets

INSM has been the subject of several analyst reports. Bank of America raised their price objective on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. UBS Group lowered their price objective on Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Monday, May 12th. Finally, Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.73.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently bought and sold shares of INSM. Cullen Frost Bankers Inc. raised its position in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP bought a new stake in Insmed during the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its position in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Finally, Spire Wealth Management bought a new stake in Insmed during the 4th quarter valued at $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.